Based on these results, the United States (US) National Comprehensive Cancer Network (NCCN) guidelines and the Japanese lung cancer practice guidelines recommend alectinib as the first-line treatment for ALK-p advanced NSCLC [3,24]. The gene discussed is ALK; the disease is lung carcinoma.